MicroSigX M3CRC Test Acclaimed at DDW 2025 Offering New Hope for CRC Prevention
We are excited to share that our plenary abstract presentation at Digestive Disease Week (DDW) 2025, delivered by CUHK research investigator Dr. Louis Ho Shing Lau, received overwhelming positive feedback and continuous enquiries from top researchers and clinicians worldwide. This recognition underscores the transformative potential of our microbiome-based diagnostic test, M3CRC.
Our microbiome-based diagnostic test for advanced neoplasia is superior to FIT, offering higher sensitivity in detecting advanced neoplasia. This innovative approach provides hope to reduce colorectal cancer (CRC) risk through monitoring and intervention of the gut microbiome.
The promising results from our multicenter study highlight M3CRC's potential to make a significant societal impact. By enhancing early detection and opening new approach for prevention, M3CRC aims to improve patient outcomes and reduce healthcare costs. As we prepare for market entry in China, we are poised to make this high-accuracy screening tool widely accessible, delivering substantial value to both patients, medical professionals and healthcare systems.
Thank you for your great feedback and continuous enquiries at DDW 2025. Stay tuned for more updates as we advance toward a future where colorectal cancer screening is more accurate and accessible.
#MicroSigX
#M3CRC
#ColorectalCancer
#CancerScreening
#GutMicrobiome
#HealthcareInnovation
#DDW2025
GenieBiome Limited 精進微生物科技有限公司
Microbiota I-Center (MagIC) (香港微生物菌群創新中心)
CUHK Medicine
